NCT06957431View on ClinicalTrials.gov

Zanzalintinib Combined With Eribulin in Advanced Liposarcoma and Leiomyosarcoma

PHASE1Not yet recruitingINTERVENTIONAL

Enrollment

18

Participants

Timeline

Start Date

September 30, 2025

Primary Completion Date

October 31, 2028

Study Completion Date

September 30, 2033

Conditions

Advanced LeiomyosarcomaAdipocytic SarcomaAdvanced Liposarcoma

Interventions

DRUG

Zanzalintinib

Supplied by Exelixis, Inc.

DRUG

Eribulin

1.1 mg/m\^2 dose.

Trial Locations (1)

63110

Washington University School of Medicine, St Louis

Sponsors

Collaborators (1)

All Listed Sponsors

lead

Washington University School of Medicine

OTHER

collaborator

Exelixis

INDUSTRY

NCT06957431 - Zanzalintinib Combined With Eribulin in Advanced Liposarcoma and Leiomyosarcoma | Biotech Hunter | Biotech Hunter